ZA95463B - Use of interleukin-12 to prevent graft-versus-host disease - Google Patents

Use of interleukin-12 to prevent graft-versus-host disease

Info

Publication number
ZA95463B
ZA95463B ZA95463A ZA95463A ZA95463B ZA 95463 B ZA95463 B ZA 95463B ZA 95463 A ZA95463 A ZA 95463A ZA 95463 A ZA95463 A ZA 95463A ZA 95463 B ZA95463 B ZA 95463B
Authority
ZA
South Africa
Prior art keywords
interleukin
versus
host disease
prevent graft
prevent
Prior art date
Application number
ZA95463A
Other languages
English (en)
Inventor
Megan Sykes
Stanley F Wolf
Original Assignee
Genetics Inst
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, Gen Hospital Corp filed Critical Genetics Inst
Publication of ZA95463B publication Critical patent/ZA95463B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA95463A 1994-01-21 1995-01-20 Use of interleukin-12 to prevent graft-versus-host disease ZA95463B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/186,529 US5573764A (en) 1994-01-21 1994-01-21 Use of interleukin-12 to prevent graft versus host disease

Publications (1)

Publication Number Publication Date
ZA95463B true ZA95463B (en) 1995-09-27

Family

ID=22685309

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95463A ZA95463B (en) 1994-01-21 1995-01-20 Use of interleukin-12 to prevent graft-versus-host disease

Country Status (14)

Country Link
US (2) US5573764A (fr)
EP (1) EP0739212B1 (fr)
JP (1) JP3825043B2 (fr)
AT (1) ATE215380T1 (fr)
AU (1) AU698410B2 (fr)
CA (1) CA2181568C (fr)
DE (1) DE69526206T2 (fr)
DK (1) DK0739212T3 (fr)
ES (1) ES2179096T3 (fr)
IL (1) IL112373A (fr)
PT (1) PT739212E (fr)
TW (1) TW349021B (fr)
WO (1) WO1995019786A1 (fr)
ZA (1) ZA95463B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
WO1997016203A1 (fr) * 1995-11-01 1997-05-09 Genetics Institute, Inc. Procedes d'administration d'il-12
EP0956301A2 (fr) * 1996-10-18 1999-11-17 Valentis Inc. Expression du gene il-12, systemes d'apport et utilisations
JP2001503258A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド 遺伝子発現および搬送系および用途
AU6150498A (en) * 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
WO1998051327A1 (fr) * 1997-05-16 1998-11-19 Toray Industries, Inc. Agent therapeutique, procede de traitement, agent prophylactique et procede prophylactique destines au traitement de maladies immunologiques chez les chiens et les chats
EP1516630A3 (fr) * 1997-10-31 2006-05-03 Wyeth Utilisation d'anticorps anti-il12 pour empêcher le rejet des greffes
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
WO2003020904A2 (fr) * 2001-08-31 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Procedes de generation de cellules cd4+ th1 humaines
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040175827A1 (en) * 2001-07-02 2004-09-09 Fowler Daniel H. Methods of generating human cd4+ th2 cells and uses thereof
WO2003038062A2 (fr) * 2001-10-31 2003-05-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Generation et utilisation de cellules tc1 et tc2
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
BRPI0818287A2 (pt) * 2007-10-08 2015-11-03 Intrexon Corp células dendríticas manipuladas e usos para o tratamento do câncer.
US20100272863A1 (en) * 2009-04-24 2010-10-28 Griebel Jonathan M Soft shaped tortillas
US9878012B2 (en) 2010-05-18 2018-01-30 Neumedicines, Inc. IL-12 formulations for enhancing hematopoiesis
WO2012174056A1 (fr) 2011-06-13 2012-12-20 Neumedicines, Inc. Mitigation d'une lésion cutanée par il-12
CA2843014C (fr) 2011-07-27 2020-01-21 Neumedicines, Inc. Utilisation d'il-12 pour generer de l'erythropoietine endogene
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP2766035B1 (fr) * 2011-10-11 2018-03-28 Universität Zürich Prorektorat MNW Combinaison médicamenteuse comprenant de l'il-12 et un agent de blocage de molécules inhibitrices des lymphocytes t pour une thérapie anti-tumorale
JP2015505326A (ja) 2012-01-18 2015-02-19 ニューメディシンズ，インコーポレーテッド 放射線防護及び放射線誘発性毒性緩和のためのｉｌ−１２
WO2013158959A1 (fr) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions et procédés pour le traitement de la maladie du greffon contre l'hôte
CN115916261A (zh) * 2020-04-17 2023-04-04 小利兰·斯坦福大学董事会 工程化il-12和il-23多肽及其用途
US12071633B2 (en) * 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
CA3234552A1 (fr) 2021-10-20 2023-04-27 Synthekine, Inc. Cytokines fc heterodimeres et leurs utilisations
US20240041939A1 (en) * 2021-12-17 2024-02-08 William Marsh Rice University Encapsulated cells expressing il-12 and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
ATE215380T1 (de) 2002-04-15
EP0739212A1 (fr) 1996-10-30
WO1995019786A1 (fr) 1995-07-27
US5756085A (en) 1998-05-26
CA2181568C (fr) 2007-09-18
ES2179096T3 (es) 2003-01-16
DE69526206T2 (de) 2002-11-21
DK0739212T3 (da) 2002-06-03
US5573764A (en) 1996-11-12
JPH09508371A (ja) 1997-08-26
AU698410B2 (en) 1998-10-29
IL112373A0 (en) 1995-03-30
DE69526206D1 (de) 2002-05-08
PT739212E (pt) 2002-08-30
JP3825043B2 (ja) 2006-09-20
IL112373A (en) 2006-08-01
TW349021B (en) 1999-01-01
EP0739212B1 (fr) 2002-04-03
CA2181568A1 (fr) 1995-07-27
AU1687595A (en) 1995-08-08

Similar Documents

Publication Publication Date Title
ZA95463B (en) Use of interleukin-12 to prevent graft-versus-host disease
UA32429C2 (uk) Засіб для лікування нетримання сечі
PL326653A1 (en) Application of epinastin in pain relieving treatments
PH31600A (en) Methods of inhibiting atrophy of the skin and vagina.
ZA931174B (en) Treatment of disease employing hyaluronic acid and nsaids.
EP0924983A4 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
IL102106A0 (en) Arylethers,their manufacture and methods of treatment
PL324750A1 (en) Expressive construct p16 and posiibility of using it in treating carcinomas
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
ZA935575B (en) Therapeutic agent and its use.
ES8403884A1 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
EP0437026A3 (en) Use of tandospirone in the treatment of depression
ZA929390B (en) The use of D-fenfluramine and fenfluramine compounds in the treatment of hypertension in insulin-resistant subjects.
NO913054D0 (no) Vaginal behandlingsprosess og innretning med dusj.
EP0745597A3 (fr) Indanylpipérazines ou homopipérazines mélatonergiques
ZA977004B (en) Therapeutic product and its use
MX9700626A (es) USO DE AZASPIRANOS EN LA REPARACIaN DE COMPOSICIONES PARA TRATAR INFECCIONES OPORTUNISTAS.
GB2230443B (en) Treatment of sleep apnoea
张钦 et al. EJACULATIO DEFICIENS TREATED WITH ACUPUNCTURE REPORT OF 110 CASES
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
EP0452941A3 (en) Use of isomonools in the treatment and prophylaxis of cancer
ZA964001B (en) 3,4-Disubstituted-phenylsulphonamides and their therapeutic use
ZA963998B (en) 3,4-Disubstituted-phenylsulphonamides and their therapeutic use
EG19049A (en) Solid thiocarbonates and methods of manufacture and use.
GEP19971009B (en) Flupirtine in combination with antiparkinsonica against muscle bracing